As Delhi’s AQI hits a new high, it is essential to know the effect it can have on our skin. Know the preventive measures from ...
MJH Life Sciences®, a premier provider of health care events, media, and education, today announced the acquisition of the Revolutionizing Atopic Dermatitis (RAD) Annual Meeting, a preeminent ...
The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...
Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...
The researchers utilized a Fra-2 transgenic mouse model that encompasses many of the features of systemic sclerosis in humans, including spontaneous systemic inflammation and fibrosis in the lungs, ...
Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care ...
The company's FDA-approved drug Sofdra is the first for the common and embarrassing condition of excessive sweating.
The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.
The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.
Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is tivumecirnon, a phase 2 oncology med being ...
Coming up in 2025, we expect to file the IND for ARQ-234, our biologic CD200 Receptor agonist for atopic dermatitis. And we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback